Cannabis Science New Management Files First 10K Annual Report, Opens In-House Investor Relations Department in Southern Florida, and Prepares to Announce Several Expansions and Advancements for Each of Its Divisions

May 7, 2010

COLORADO SPRINGS, Colo. - Cannabis Science, Inc. (OTCBB:CBIS - News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has successfully completed filing its first 10K annual report with the SEC under its new management, and that the 'E' has been officially removed from its OTCBB symbol. Its symbol (CBIS) is fully restored as of today.

Richard Cowan, Cannabis Science Inc., Chief Financial Officer, stated, "The delay was not the result of any substantive legal or accounting problems, but from the intricacies of reporting the financial transition in the company's business over the last year into our current business model under Cannabis Science President and CEO Dr. Robert Melamede PhD."

In an effort to promptly and effectively communicate the outstanding progress the Company has made, Cannabis Science has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS(2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.

Mr. Cowan concluded, "The past few months have been very positive for the Company's expansion and progress, and several new revenue opportunities are being assessed and negotiated. The Company will be making the required announcements over the next few days outlining the new business expansions and relationships. Most of these developments result from the enormous amount of interest and communications from the media, potential partners, patients, and our outstanding and growing list of shareholders. Our new Investor Relations Department will help us tremendously in our efforts to give timely and accurate information to our shareholders and the public. Mr. Friedman and his associates are very quickly ramping up their knowledge base in regards to our past, present, and future developments so please feel free to give us a call and introduce yourself."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CONTACT
Cannabis Science, Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Investor Relations
Mark J. Friedman
1.877.431.CBIS
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com